The oncogenic activity of doxorubicin and daunorubicin, given i.v. once at the dose of 5 and 10 mg/kg, respectively, to male and female BALB/c mice, was examined. Compared with controls treated with a saline solution, about 1 year after administration, no significant statistical differences was noted in tumor incidence. The data obtained differ greatly from the considerable oncogenic power demonstrated by the 2 drugs with regards to rats.
Get full access to this article
View all access options for this article.
References
1.
BachurN.R.: Adriamycin (NSC-123127) pharmacology. Cancer Chemother. Rep., 16: 153–158, 1975.
2.
BernardJ., PaulR., BoironM., JacquillatC., MaralR.: Rubidomycin: A new agent against cancer. Rec. Results Cancer Res., 20: 73–76, 1969.
3.
BertazzoliC.: La Daunoblastina. Farmitalia. Aggiornamenti clinico-terapeutici. Vol. 11, pp. 154–202, Ed. Minerva Medica, Torino, 1970.
4.
BertazzoliC., BelliniO., MagriniU., TosanaM.G.: Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse. Cancer Treat. Rep., 63: 1877–1883, 1979.
5.
BertazzoliC., ChieliT., SolciaE.: Different incidence of breast carcinomas or fibroadenomas in dounomycin-treated rats. Experientia, 27: 1209–1210, 1971.
6.
BiancifioriC.: The laboratory manufacture of pelleted diets for mice. Lav. Ist. Anat. Istol. Patol. Perugia, 24: 189–194, 1964.
7.
BiancifioriC., BucciarelliE., ClaysonD.B., SantilliE.: Induction of hepatomas in CBA/Cb/Se mice by hydrazine sulphate and the lack of effect of croton oil on tumor induction in BALB/c/Cb/Se mice. Br. J. Cancer, 18: 544–550, 1964.
8.
BucciarelliE.: Mammary tumor induction in male and female Sprague-Dawley rats by adriamycin and daunomycin. J. Natl. Cancer Inst., 66: 81–84, 1981.
9.
BucciarelliE., BinazziR., SantoriP., VespasianiG.: Sindrome nefrosica nei ratti da adriamycin cloridrato. Lav. 1st. Anat. Patol. Perugia, 36: 53–69, 1976.
10.
BucciarelliE., ProvvidenzaM., SantoriP., VespasianiG.: Oncogenesi da adriamicina e daunomicina in ratti maschi e femmine Sprague-Dawley. Dati preliminari. Lav. Ist. Anat. Istol. Patol. Perugia, 24: 71–81, 1978.
11.
CasazzaA.M., BelliniO., FormelliF., GiulianiF., LenzaL., MagriniU.: Tumors and dental and ocular abnormalities after treatment of infant rats with adriamycin. Tumori, 63: 331–338, 1977.
12.
DraganiT.A.: Analysis of tumor incidence in BALB/c mice used as controls in carcinogenicity experiments. Tumori, 65: 655–675, 1979.
13.
MaltoniC., ChiecoP.: Adriamicina: un nuovo potente cancerogeno. Gli Ospedali della Vita, 2: 107–109, 1975.
14.
MarquardtH., PhilipsF.S., MarquardtH., SternbergS.S.: Oncogenicity of 4-demethoxydaunomycin (DMD): lack of correlation among in vitro short-term tests and between in vitro and in vivo findings. Proc. Am. Ass. Cancer Res. and Asco20(no. 181), p. 45, 1979.
15.
MarquardtH., PhilipsF.S., SternbergS.S.: Tumorigenicity « in vivo » and induction of malignant transformation and mutagenesis in cell cultures by adriamycin and daunomycin. Cancer Res., 36: 2065–2069, 1976.
16.
PhilipsF.S., GilladogaA., MarquardtH., SternbergS.S., VidalP.M.: Some observations on the toxicity of adriamycin (NSC-123127). Cancer Chemother. Rep., 6: 177–181, 1975.
17.
SolciaE., BalleriniL., BelliniO., SalaL., BertazzoliC.: Mammary tumors induced in rats by adriamycin and daunomycin. Cancer Res., 38: 1444–1446, 1978.
18.
SternbergS.S.: Cross-striated fibrils and other ultrastructural alterations in glomeruli of rats with daunomycin nephrosis. Lab. Invest., 22: 31–51, 1970.
19.
SternbergS.S., PhilipsF.S., CroninA.P.: Renal tumors and other lesions in rats following a single intravenous injection of daunomycin. Cancer Res., 32: 1029–1036, 1972.
20.
YesairD.W., SchwartzbachE., ShukD., DenineE.P., AsbelM.A.: Comparative pharmacokinetics of daunomycin and adriamycin in several animal species. Cancer Res., 32: 1177–1183, 1972.
21.
YoungD.M.: Pathologic effects of adriamycin (NCS 123127) in experimental systems. Cancer Chemother. Rep., 6: 153–158, 1975.
